•  

Posts Tagged: Ontario Brain Institute (OBI)

Baycrest’s “My Virtual Dream” brain exhibit at Ontario Science Centre Jan 17-18, 2015

MaRS Innovation is a My Virtual Dream event sponsor and commercialization partner Toronto, ON (January 12, 2015) – Baycrest Health Sciences’ dazzling brain science exhibit from 2013 Scotiabank Nuit Blanche will be on show at the Ontario Science Centre’s BRAINFest, Jan. 17-18. My Virtual Dream is an innovative and interactive live performance experience at the intersection of science, art and music.  The installation will enable participants to use their brain waves to communicate with each other through an immersive audio and visual expression that ... Read more

Holland Bloorview’s Anxiety Meter included in Globe and Mail’s neuroscience feature

"Research labs across Ontario are full of ingenious – and even life-saving – inventions. Unfortunately, many of them never make it to market," writes Wendy Leung in "These six great neuroscience ideas could make the leap from lab to market" in the November 20, 2014 edition of the Globe and Mail. MaRS Innovation, which was created to help researchers solve exactly this problem, has a project with Holland Bloorview Kids Rehabilitation Hospital that was featured in Leung's article. Asim Siddiqi founded the anxiety ... Read more

Dr. Raphael Hofstein’s MRI blog post: How Team Ontario’s biotechnology takes on the world

Dr. Raphael (Rafi) Hofstein is president and CEO of MaRS Innovation (MI) – the commercialization agent for an exceptional research discovery pipeline stemming from 16 leading Ontario academic institutions. As a single entry point to annual member research and development activity of $1B, MI provides a gateway for investors and licensees who wish to access Ontario’s technology assets. During the 2012 BIO convention in Boston, Dr. Hofstein blogged about how CQDM of Montreal and MaRS Innovation of Toronto had teamed up to ... Read more

Business Without Borders features Encycle Therapeutics, Raphael Hofstein

Encycle Therapeutics, a MaRS Innovation spin-off company, was featured by Business Without Borders' High Tech section in a Q&A profile with MI's President and CEO, Raphael Hofstein. Here's an excerpt: Business Without Borders (BWB): What makes Encycle’s technology so promising? Raphael Hofstein (RH): Proteins are made of smaller units called peptides, usually existing as linear chains. If they get into the bloodstream, they get degraded rapidly by enzymes and they find it very difficult to get into cells of the body. What we want ... Read more

Montreal’s La Presse covers life science research funding project among MI, CQDM, OCE and OBI

This week, MaRS Innovation (MI) announced a new partnership agreement with The Québec Consortium for Drug Discovery (CQDM), the Ontario Brain Institute (OBI) and Ontario Centres of Excellence (OCE) to launch the Québec/Ontario CQDM Funding Program. The funding program will support collaborative life science research projects between the two provinces that seek to develop new tools for biopharmaceutical research. (more…) Read more

CQDM Partners with MaRS Innovation, Ontario Brain Institute and Ontario Centres of Excellence to Launch Life Sciences Funding Program Within Ontario-Québec Corridor

BOSTON, MA, June 18, 2012 — Together with key partners from Ontario, The Québec Consortium for Drug Discovery (CQDM) is creating a new initiative to fund collaborative life sciences research projects between the two provinces. A French version of this release is available via CQDM's website. This initiative is the first notable and concrete realization of the Ontario-Québec Life Sciences Corridor, announced at the 2011 BIO International Convention. It builds upon two previous pilot projects and existing strengths within the two provinces to ... Read more

Encycle Therapeutics Launches Ground-Breaking Chemistry Platform

Platform for cyclizing peptides promises to increase efficiency of early-stage drug discovery BOSTON, June 18, 2012 - Encycle Therapeutics, a MaRS Innovation spin-off company, has created a ground-breaking chemistry platform for cyclizing peptides that promises to increase the efficiency of the early-stage drug discovery process. Peptides have long been sought after as therapeutics due to their high specificity — they can hit specific cellular targets, especially complex protein-protein interaction targets implicated in cancer, cardiovascular disease and metabolic disorders. (more…) Read more